Sector News

Stryker to build new innovation centre in Cork

September 23, 2014
Life sciences
US medical technologies company Stryker is to build a new 44,000 square foot surgical innovation centre in Cork, which will combine all Ireland-based research and new product development activities and support functions within one purpose-built facility. Construction is set to commence in the last months of this year, with completion expected in Q4 2015.
 
“This state-of-the-art facility will drive innovation by giving us the ability to design, develop and test new products in conditions that mimic real life,” Stryker Instruments President Jim Heath said.
 
The innovation centre, which Stryker says will fuel future growth, will focus on the research and development of products, technologies and solutions to reduce surgical procedure time and healthcare costs while improving surgical precision and clinical outcomes in the areas of bone cutting, soft tissue dissection and adjacent areas across a broad spectrum of surgical specialities and procedures. It is being constructed with the support of the IDA.
 
Stryker says the facility will feature state-of-the-art R&D facilities for product design and process development and a customer experience laboratory that will allow engineers and surgeons to test and evaluate new ideas, technology and product designs in a simulated operating room and surgical environment.
Stryker first came to Ireland in 1998 and now employs over 2,200 people at four sites between Cork and Limerick, including over 150 people in research and development.
 
Source: Irish Times

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”